Exchange: NASDAQ·Updated 07:37 PM EDT
TGTX logo

TGTXTG Therapeutics Inc

$56.04
$0.54
(0.97%)
Today
Closed $56.04
$0.54
(0.96%)
After Hours
EarningsAug 3
Mkt Cap$8.58B
Vol1.44M
News
all
press releases
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...
PR Newswire
More News
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations...
Yahoo! Finance: News
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch
Bank of America analyst Alec Stranahan raised his price target on TG Therapeutics to $20 from $17 but kept an ‘Underperform’ rating on the shares.
Stocktwits
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Zacks
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
Zacks
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.read more...
Benzinga
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug.
Stocktwits
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Zacks
<
1
2
...
>